Adverse events of apatinib in the treatment of stage IV osteogenic sarcoma that did not respond to chemotherapy
| Adverse event* | Grade 1 | Grade 2 | Grade 3 | Total |
|---|---|---|---|---|
| Hand-foot syndrome | 8 | 4 | 0 | 12 (35.29%) |
| Proteinuria | 9 | 1 | 1 | 11 (32.35%) |
| Hypertension | 8 | 3 | 0 | 11 (32.35%) |
| Mucositis | 3 | 1 | 0 | 4 (11.76%) |
| Fatigue | 3 | 1 | 0 | 4 (11.76%) |
| Anemia | 4 | 0 | 0 | 4 (11.76%) |
| Transaminase increase | 4 | 0 | 0 | 4 (11.76%) |
| Hiccups | 4 | 0 | 0 | 4 (11.76%) |
| Pain | 0 | 3 | 0 | 3 (8.82%) |
| Diarrhea | 3 | 0 | 0 | 3 (8.82%) |
| Skin pigmentation | 3 | 0 | 0 | 3 (8.82%) |
| Periodontal disease | 3 | 0 | 0 | 3 (8.82%) |
| Rash | 3 | 0 | 0 | 3 (8.82%) |
| Bilirubin increase | 3 | 0 | 0 | 3 (8.82%) |
| Pneumothorax | 2 | 0 | 0 | 2 (5.88%) |
| Dysgeusia | 0 | 0 | 1 | 1 (2.94%) |
| Apositia | 0 | 1 | 0 | 1 (2.94%) |
| Hematuria | 1 | 0 | 0 | 1 (2.94%) |
| Dyspnea | 1 | 0 | 0 | 1 (2.94%) |
| Total | 62 | 14 | 2 | 78 |
*According to CTCAE5.0.